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group, there were nine lives saved compared with the
NSAID group with 18 life-years gained for each death
avoided. The total cost/life saved with Celecoxib was
25,458,588 pesetas (US $131,909) with a cost/life-year
gained of 1,414,366 pesetas (US $7,328) when compared
with the use of NSAIDs.
CONCLUSIONS: The use of Celecoxib instead of
NSAIDs to treat osteoarthritis will produce a lower inci-
dence of severe G-I complications, thus avoiding deaths.
The cost per life-year gained when using Celecoxib is a
reasonable amount, easily covered by the Spanish NHS.
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OBJECTIVES: To perform an economic evaluation on
the short-term costs of managing edema and hyperten-
sion in COX-2-inhibitor-treated patients with osteoar-
thritis (OA) and hypertension (HTN).
METHODS: Two randomized clinical trials (RCT) in
OA/HTN patients showed a significantly higher inci-
dence of systolic blood pressure (SBP) destabilization
(8.7% to 15.6%; RR  0.61, p  .001), edema (4.8% to
8.5%, RR  0.67, p  0.04), and both SBP/edema (0.6%
to 2.2%; RR  0.28, p  0.003) for rofecoxib 25 mg/day
(n  942) compared to celecoxib 200 mg/day (n  960).
The RCT results were projected onto a typical US man-
aged-care organization (MCO) population using: (1) the
age distribution from a large MCO; (2) age- and gender-
specific prevalence of OA and HTN from US government
data; (3) age-specific incidence of cardiorenal events from
pooled RCT data, and (4) prevalence of COX-2 inhibitor
use in a large insurer. We determined resource utilization
and treatment patterns from the published literature and
an expert physician panel. Costs were obtained from
standardized databases and published literature.
RESULTS: For a population of 1,000,000 MCO mem-
bers, 8% of members (n  79,903) are projected to have
OA and HTN, while 2.2% of members (n  21,594) have
OA /HTN and use a COX-2 inhibitor. From the analysis,
the number of additional events predicted to occur with
rofecoxib (relative to celecoxib) are: SBP destabilization
(n  1144); edema-alone (n  453); edema and SBP de-
stabilization (n  345). The total cost savings of treat-
ment with celecoxib would be $474,007. Translated into
other parameters, the cost savings from the celecoxib us-
age would be $1.83 in per patient per month costs, and
$0.24 in the daily cost of COX-2 inhibitor use for an av-
erage patient.
CONCLUSION: The short-term management of SBP de-
stabilization and edema adds to the cost of rofecoxib treat-
ment, relative to celecoxib. Clinicians and payers should
not ignore the clinical effects and economic impact of ar-
thritis medications on blood pressure and edema.
PAO8
THE COST-EFFECTIVENESS OF INFLIXIMAB FOR 
SEVERE RHEUMATOID ARTHRITIS
Barbieri M1, Wong JB2, Drummond MF3
1University of York, York, UK; 2Tupper Research Institute, New 
England Medical Center, Boston, MA, USA; 3University of York, 
York, UK
RA is a chronic disease that affects 0.5 to 1% of the pop-
ulation. The economic impact of RA on individuals and
society is enormous and the costs of RA rise steeply with
disease severity. A therapy that reduces disease progres-
sion could be expected to lead to reductions in resource
use as well as maintaining quality of life.
OBJECTIVE: To estimate the costs and consequences of
adding infliximab to the care of patients with severe rheuma-
toid arthritis (RA) already being treated with methotrexate.
METHODS: Estimates of the impact of infliximab on dis-
ease progression were obtained from the ATTRACT trial
in which 428 RA patients were randomly assigned to
methotrexate or methotrexate plus infliximab. Since pa-
tients in the ATTRACT trial were followed for only 54
weeks, we developed a Markov model in order to estimate
the long-term consequences of RA. The model was based
on a cohort (ARAMIS) involving 4258 consecutively en-
rolled RA patients followed in nine centres in USA and
Canada. Markov health states were based on the Health
Assessment Questionnaire and on drug treatment. For the
first year, costs were calculated using the resource utiliza-
tion by UK patients in the ATTRACT trial and applying
UK unit costs. Long-term costs were obtained from the
Norfolk Arthritis Register (NOAR) cohort. Utilities were
based on visual analogue scale assessments in ATTRACT
(first year) and ARAMIS (long-term).
RESULTS: In the base-case analysis, the incremental cost
per QALY of infliximab was £33,618. Assuming radio-
graphic stabilization of joint disease for patients treated
with infliximab after the first year of treatment (as sug-
gested in the long-term data from the ATTRACT trial)
the cost-effectiveness ratio falls to £5111 per QALY. Sen-
sitivity analyses were performed to allow for uncertainty
in some of the estimates.
CONCLUSION: Infliximab is likely to be a cost-effective
treatment for patients suffering from severe RA.
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